RxDoctor Payments Data

Shawn Marhamati, MD

Urology · Woodbridge, VANPI 1114312808

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $116,006 of the $129,703 with a category attached, or 89.4%. Procept Biorobotics Corporation accounts for 97.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $98,059, more than ten times the $589 reported in 2021. Among urology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$129,703in general payments, 2019–2025

Across 137 payments — averaging $946.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$127K
  • Angiodynamics, Inc.$1K
  • Medtronic$524
  • Laborie Medical Technologies Corp.$347
  • Calyxo, Inc.$319
  • Olympus America Inc.$206
  • plus $197 from 5 others

What the payments were for

  • Consulting fees$116,00689%
  • Travel & lodging$9,8358%
  • Food & beverage$3,7973%
  • Education$650%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,703 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$349,285
Medicare patients
709
Services billed
5,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix113$297,153
YonsaAbiraterone Acet,submicronized18$188,475
Abiraterone Acetate69$76,727
MyrbetriqMirabegron15$9,384
Trospium Chloride93$6,585
Methenamine Hippurate65$4,014
Tamsulosin Hcl145$1,939
Estradiol28$1,797
Potassium Citrate ErPotassium Citrate22$1,796
Trospium Chloride ErTrospium Chloride15$1,599
Alfuzosin Hcl ErAlfuzosin Hcl49$1,175
Oxybutynin Chloride ErOxybutynin Chloride20$343
Ciprofloxacin Hcl43$228
Prednisone46$138
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim39$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$65$9,38415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.

Other urology in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →